Sana Biotechnology：干细胞来源的同种异体CD19 CAR-T细胞疗法SC291, 当前处于临床一期。HIP: Hypoimmune CAR-T Platform
发布于 广东
Sana Biotechnology：干细胞来源的同种异体CD19 CAR-T细胞疗法SC291, 当前处于临床一期。HIP: Hypoimmune CAR-T Platform